B7-33, identified by its CAS number 1818415-56-3, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. While specific characteristics such as its molecular structure, solubility, and stability may vary, compounds in this category typically exhibit properties that make them suitable for pharmaceutical development. B7-33 is often formulated in various dosages, such as 2 mg, 5 mg, and 10 mg, to accommodate different therapeutic needs and patient responses. The compound may act on specific biological targets, influencing pathways relevant to disease processes. Its pharmacokinetics, including absorption, distribution, metabolism, and excretion (ADME), are crucial for determining its efficacy and safety profile. As with many investigational drugs, ongoing research is essential to fully elucidate its mechanism of action, potential side effects, and overall therapeutic potential. Always consult scientific literature or databases for the most current and detailed information regarding this compound.

B7-33 is a selective relaxin receptor 1 (RXFP1) agonist. It binds to RXFP1 and preferentially activates thepERK pathway over cAMP in cells (with RXFP1 expression).

B7-33 2mg/5mg/10mg

1818415-56-3: B7-33, identified by its CAS number 1818415-56-3, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential therapeutic applications. While specific characteristics such as its molecular structure, solubility, and stability may vary, compounds in this category typically exhibit properties that make them suitable for pharmaceutical development. B7-33 is often formulated in various dosages, such as 2 mg, 5 mg, and 10 mg, to accommodate different therapeutic needs and patient responses. The compound may act on specific biological targets, influencing pathways relevant to disease processes. Its pharmacokinetics, including absorption, distribution, metabolism, and excretion (ADME), are crucial for determining its efficacy and safety profile. As with many investigational drugs, ongoing research is essential to fully elucidate its mechanism of action, potential side effects, and overall therapeutic potential. Always consult scientific literature or databases for the most current and detailed information regarding this compound.

B7-33 is a single-chain relaxin analog and a selective agonist for relaxin receptor 1 (RXFP1). It binds to RXFP1 and preferentially activates the pERK pathway in cells expressing RXFP1, rather than cAMP. B7-33 serves as an antifibrotic agent and provides cardioprotective effects.

CAS 1818415-56-3

B7-33 2mg/5mg/10mg

B7-33

Ref: TM-TP2903